Healthcare & Pharmaceutical Market Research in Canada

BioNixus is a leading healthcare market research company in Canada, delivering TCPS 2-compliant HCP surveys, KOL mapping, and payer landscape research aligned with Health Canada, CADTH, and provincial formulary requirements. BioNixus combines primary research depth with physician access across major Canadian academic medical centres and specialist community networks — in both English and French.

A healthcare market research company in Canada designs and executes studies covering physician prescribing behaviour, provincial payer and formulary access dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the Canadian market.

Canada's system is publicly funded but provincially administered. Health Canada approval does not guarantee market access — commercial outcomes depend on CADTH health technology assessments, pCPA pan-Canadian price negotiations, and individual provincial formulary listing decisions (Ontario ODB, Quebec RAMQ/INESSS, BC PharmaCare, Alberta ADBL), each with distinct evidence requirements and timelines. PMPRB pricing oversight adds further strategic complexity for patented medicines.

BioNixus covers oncology, immunology and biologics (including provincial biosimilar mandatory switching policies), cardiovascular, diabetes and metabolic (including GLP-1), rare disease (Canadian rare disease strategy), respiratory, infectious disease, neurology, medical devices, and consumer health across the Canadian market.

Yes. BioNixus maintains physician and specialist networks across major Canadian academic medical centres including UHN (Toronto General, Princess Margaret), BC Cancer, Montreal General Hospital, Ottawa Hospital, and Sunnybrook Health Sciences Centre. For scarce specialties such as oncology or rare disease, we recruit through Canadian cancer centre networks and rare disease specialist directories. Bilingual (English and French) recruitment is available.

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including provincial payer depth interviews and advisory board modules typically run 6–10 weeks depending on therapy area, REB review requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-AMC recruitment across provinces may require extended planning timelines.

Yes. BioNixus designs and executes Canadian patient research in compliance with PIPEDA/CPPA data privacy standards and TCPS 2 research ethics requirements. All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling consistent with provincial privacy legislation.

Yes. Canadian modules can run with comparable cells in the USA, UK, EU5 (Germany, France, Italy, Spain), Brazil, Saudi Arabia, and UAE — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner.